CPHI
China Pharma Holdings, Inc.
There isn't enough reported data to score CPHI yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CPHI Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Stable | |
| Weak |
CPHI's cash flow is currently stable, but its revenue, profitability and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CPHI PE Valuation
CPHI has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CPHI Forward outlook
There aren't enough analyst estimates for CPHI to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CPHI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.42 | +$1.08 |
| Q1 2026 | -$0.54 | +$1.70 |
| Q4 2025 | -$0.74 | +$1.96 |
| Q3 2022 | -$35.00 | +$10.00 |
| Q2 2022 | -$35.00 | +$10.00 |
| Q1 2022 | -$35.00 | $0.00 |
| Q4 2021 | -$35.00 | $0.00 |
| Q3 2021 | -$45.00 | +$190.00 |
CPHI lost $0.42 per share over the past year, a smaller loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CPHI on earnings quality, reporting a profit while its opponent remains loss making.
CPHI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $948.3K | -7.5% |
| Q1 2026 | $983.5K | -13% |
| Q4 2025 | $1.2M | +8.1% |
| Q3 2025 | $756.2K | -31% |
| Q2 2025 | $1M | +11% |
| Q1 2025 | $1.1M | -17% |
| Q4 2024 | $1.1M | -47% |
| Q3 2024 | $1.1M | -39% |
CPHI's revenue has slid since its 2020 peak: $948,340 last quarter, down 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -151% | -87 points |
| Q1 2026 | -114% | -47 points |
| Q4 2025 | -98% | +7.6 points |
| Q3 2025 | -83% | +16 points |
| Q2 2025 | -64% | +87 points |
| Q1 2025 | -67% | +0.1 points |
| Q4 2024 | -105% | -50 points |
| Q3 2024 | -99% | -59 points |
CPHI's operating margin was −151% last quarter, down 87 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CPHI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CPHI on profitability, with a higher operating margin.
CPHI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2025 | -$237.6K | -$190.6K |
| Q2 2025 | $291.1K | +$363.9K |
| Q1 2025 | -$116.1K | +$469K |
| Q3 2024 | -$47K | -105% |
| Q2 2024 | -$72.7K | +$143.7K |
| Q1 2024 | -$585.2K | +$883.1K |
| Q4 2023 | -$22.3K | -104% |
| Q3 2023 | $1M | +$1M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with CPHI at up 110%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
CPHI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +58% | +14.9M shares |
| 1 year | +1142% | +37.3M shares |
| 3 years | +40409% | +40.4M shares |
| 5 years | +46392% | +40.4M shares |
| Available history | +46392% | +40.4M shares |
CPHI has 41M diluted shares, up 1142% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CPHI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CPHI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | 1,068.6x | High |
| Q1 2022 | 217.7x | High |
| Q4 2021 | 20.8x | High |
| Q1 2021 | 92.7x | High |
| Q4 2020 | 42.3x | High |
CPHI's net debt is more than 20 years of its operating earnings (EBITDA), up from more than 20 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CPHI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.4 | Neutral |
| Stochastic | 5.4 | Oversold |
CPHI's weekly RSI is 41 (neutral) and its Stochastic is 5 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CPHI PE vs Healthcare Sector
CPHI has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CPHI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.68 | 18% below |
| 20 week MA | $0.84 | 33% below |
| 50 week MA | $0.86 | 35% below |
| 100 week MA | $1.37 | 59% below |
| 200 week MA | $5.78 | 90% below |
CPHI is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CPHI on trend strength, trading above more of its moving averages.
CPHI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $121.5 | $223.8 | +84% |
| 2021 | $223.8 | $215.1 | -3.9% |
| 2022 | $215.1 | $58.3 | -73% |
| 2023 | $58.3 | $6.05 | -90% |
| 2024 | $6.05 | $2.10 | -65% |
| 2025 | $2.10 | $1.29 | -39% |
| 2026 YTD | $1.29 | $0.56 | -57% |
CPHI has finished five years in a row lower, and it's down 57% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CPHI on returns for 2026, with the stronger performance.